SEC Filings

Form 8-K/A
PROTAGONIST THERAPEUTICS, INC filed this Form 8-K/A on 07/31/2017
Document Outline
Entire Document (942.3 KB)
Subdocument 1 - 8-K/A - 8-K/A
Page 1 - UNITED STATES
Page 2 - Explanatory Note
Page 3 - SIGNATURES
Page 4 - INDEX TO EXHIBITS
Subdocument 2 - EX-10.1 - EX-10.1
Page 1 - Exhibit 10.1
Page 2 - TABLE OF CONTENTS
Page 3 - LICENSE AND COLLABORATION AGREEMENT
Page 4 - Acquirer
Page 5 - CD
Page 6 - Clinical Trial
Page 7 - Commercialization
Page 8 - Cover
Page 9 - Diligent Efforts
Page 10 - FTE Rate
Page 11 - Governmental Authority
Page 12 - License Term
Page 13 - Material Safety Issue
Page 14 - N/A
Page 15 - New Indication
Page 16 - Phase 1 Activities
Page 17 - Phase 2
Page 18 - Phase 2B Activities
Page 19 - Public Health Service Act
Page 20 - Retained Compound
Page 21 - Additional Definitions.
Page 22 - N/A
Page 23 - Article 2
Page 24 - Subcommittee
Page 25 - Agenda and Minutes
Page 26 - provided, however
Page 27 - provided
Page 28 - Authority
Page 29 - Article 3
Page 30 - Phase 2 CMC Development Budget
Page 31 - provided
Page 32 - Phase 1 Activities
Page 33 - Phase 2 Activities
Page 34 - Responsibility; Diligence
Page 35 - Clinical Supply Agreement
Page 36 - Development Compliance Matters
Page 37 - Clinical Study Registration and Results Reporting
Page 38 - Audited Site
Page 39 - Subcontracting Party
Page 40 - No Branding Activities
Page 41 - Article 4
Page 42 - Second Opt-In.
Page 43 - Effect of Failure to Make the Second Opt-In Election
Page 44 - Development
Page 45 - Commercialization
Page 46 - Secondary Call
Page 47 - Initial Co-Detailing Plan
Page 48 - N/A
Page 49 - Article 6
Page 50 - Sublicensing
Page 51 - provided
Page 52 - Specified Percentage
Page 53 - Development and Approval Milestones
Page 54 - Development and Approval Milestone Events in UC
Page 55 - Sales Milestones
Page 56 - Royalty Reductions
Page 57 - provided
Page 58 - Royalty Conditions
Page 59 - N/A
Page 60 - provided
Page 61 - Ownership of Collaboration Inventions, Patent Rights and Know-How
Page 62 - Right to Practice Jointly Owned Technology
Page 63 - provided
Page 64 - provided
Page 65 - Filing, Prosecution and Maintenance of Retained Patent Rights and Other Protagonist-Controlled Paten
Page 66 - CREATE Act
Page 67 - Enforcement and Defense
Page 68 - provided
Page 69 - provided
Page 70 - provided
Page 71 - provided
Page 72 - N/A
Page 73 - Article 9
Page 74 - provided
Page 75 - provided further, however,
Page 76 - Terms of this Agreement
Page 77 - Requirement to Cooperate to Enable Accurate Public Disclosure.
Page 78 - Attorney-Client Privilege.
Page 79 - Additional Representations and Warranties of Protagonist
Page 80 - N/A
Page 81 - Schedule 1.62
Page 82 - Exclusion from Federal Health Care Programs
Page 83 - No Debarred Individuals
Page 84 - Article 11
Page 85 - Conditions to Indemnification
Page 86 - Insurance
Page 87 - Termination by Janssen Without Cause
Page 88 - Termination for Bankruptcy
Page 89 - N/A
Page 90 - HSR Filing; Termination upon HSR Denial
Page 91 - provided
Page 92 - N/A
Page 93 - provided
Page 94 - Post-Termination Royalties to Janssen
Page 95 - Additional Effects of Expiration or Termination for any Reason
Page 96 - Arbitration
Page 97 - amiable compositeur
Page 98 - Entire Agreement
Page 99 - Amendment; No Waiver
Page 100 - Headings
Page 101 - Governing Law
Page 102 - [ SIGNATURE PAGE TO LICENSE AND COLLABORATION AGREEMENT ]
Page 103 - SCHEDULE 1.59
Page 104 - N/A
Page 105 - SCHEDULE 1.62
Page 106 - SCHEDULE 1.97
Page 107 - SCHEDULE 3.3.2
Page 108 - SCHEDULE 3.6.2
Page 109 - SCHEDULE 10.1.4
Page 110 - SCHEDULE 10.3.1
Page 111 - SCHEDULE 10.3.2
Page 112 - EXHIBIT A
Page 113 - EXHIBIT B
Page 114 - EXHIBIT C
Page 115 - EXHIBIT D
Page 116 - EXHIBIT E
Page 117 - EXHIBIT F
Page 118 - About the Janssen Pharmaceutical Companies
Page 119 - About Johnson Johnson Innovation
Page 120 - EXHIBIT G
Page 121 - Terms of the Collaboration
Page 122 - Forward Looking Statements
Page 123 - Contact: